Aquestive Therapeutics Inc [AQST] stock prices are down -2.24% to $6.54 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The AQST shares have gain 12.76% over the last week, with a monthly amount glided 32.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 17, 2024, and set its price target to $17. On May 10, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $8 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $10 on April 11, 2024. Raymond James initiated its recommendation with a Outperform and recommended $7 as its price target on March 28, 2024. In a note dated April 22, 2019, H.C. Wainwright initiated a Buy rating.
The stock price of Aquestive Therapeutics Inc [AQST] has been fluctuating between $2.12 and $6.86 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $6.54 at the most recent close of the market. An investor can expect a potential return of 83.49% based on the average AQST price forecast.
Analyzing the AQST fundamentals
The Aquestive Therapeutics Inc [NASDAQ:AQST] reported sales of 44.13M for trailing twelve months, representing a drop of -50.23%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -1.19%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.69, Equity is 1.09 and Total Capital is -0.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Aquestive Therapeutics Inc [NASDAQ:AQST]’s Current Ratio is 3.53. On the other hand, the Quick Ratio is 3.18, and the Cash Ratio is 2.61. Considering the valuation of this stock, the price to sales ratio is 17.93.
Transactions by insiders
Recent insider trading involved Barber Daniel, President and CEO, that happened on Sep 26 ’25 when 91343.0 shares were sold. Boyd Peter E. completed a deal on Sep 26 ’25 to sell 10000.0 shares. Meanwhile, Officer Peter Boyd bought 10000.0 shares on Sep 26 ’25.
